We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

12 hedge funds and large institutions have $2.7M invested in Cyclo Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

361% more capital invested

Capital invested by funds: $585K → $2.7M (+$2.11M)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

33% more funds holding

Funds holding: 9 → 12 (+3)

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$987K
2
State Street
State Street
Massachusetts
+$374K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$204K
4
BlackRock
BlackRock
New York
+$90.8K
5
UBS Group
UBS Group
Switzerland
+$87K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$141K

CYTH Hedge Fund Activity: Q2 2021 in Review

12 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q2 2021, worth a combined $2.7M — up 361% from $585K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CYTH positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $987K. The largest seller was AIGH Capital Management, exiting entirely with an estimated $141K sold.

  • 12 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q2 2021, up from 9 in Q1 2021.
  • Funds reported $2.7M of Cyclo Therapeutics, Inc. Common Stock stock for Q2 2021, up 361% quarter-over-quarter.
  • 4 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q2 2021 and 1 closed out, a net change of +3 holders.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q2 2021 was Vanguard Group, an estimated $987K added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q2 2021 was AIGH Capital Management, an estimated $141K sold.

Based on aggregated 13F filings for Q2 2021.